Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLRMT | O00411 | 1/20 | 0.37 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.35 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.35 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.35 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.35 |
| ▸ | P2RY1 | P47900 | 3/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.31 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | RARS1 | P54136 | 1/20 | 0.31 |
| ▸ | FHIT | P49789 | 1/20 | 0.31 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26327762 | 0.90 | POLRMT (0.39) | POLRMTP2RY2P2RY4P2RY6P2RY14 | |
| SCHEMBL26326450 | 0.86 | POLRMT (0.35) | POLRMTP2RY2 | |
| SCHEMBL26326550 | 0.86 | POLRMT (0.33) | POLRMT | |
| SCHEMBL26326530 | 0.85 | POLRMT (0.33) | POLRMT | |
| SCHEMBL26326602 | 0.84 | POLRMT (0.32) | POLRMT | |
| SCHEMBL26326630 | 0.83 | POLRMT (0.33) | POLRMT | |
| SCHEMBL26326574 | 0.83 | POLRMT (0.33) | POLRMT | |
| SCHEMBL26326474 | 0.81 | POLRMT (0.31) | POLRMT | |
| SCHEMBL25911561 | 0.81 | ADK (0.36) | POLRMT | |
| SCHEMBL26327759 | 0.80 | POLRMT (0.33) | POLRMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287029-A1 | ANTIVIRAL PRODRUGS, PHARMACEUTICAL FORMULATIONS, AND METHODS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230287029-A1 | ANTIVIRAL PRODRUGS, PHARMACEUTICAL FORMULATIONS, AND METHODS | MTAP, SARS1, RNGTT | POLRMT 20/4885P2RY2 702/4885P2RY4 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.